We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ProJect Pharmaceutics and TUM-Spin-off ImevaX Announce Agreement
News

ProJect Pharmaceutics and TUM-Spin-off ImevaX Announce Agreement

ProJect Pharmaceutics and TUM-Spin-off ImevaX Announce Agreement
News

ProJect Pharmaceutics and TUM-Spin-off ImevaX Announce Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ProJect Pharmaceutics and TUM-Spin-off ImevaX Announce Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

IMX101 is a multicomponent vaccine, making the formulation development particularly challenging.

The contract covers activities in developing a rational formulation based on ProJect Pharmaceutics´ Predictive Formulation Analytics. This technology offers an innovative scientific approach for designing optimized protein formulations by determining the most favorable composition for the native structure of the protein with regard to its intra- and intermolecular physicochemical properties. By analyzing the response to certain excipients the most promising formulation candidates can be identified quickly and reliably reducing the need for extensive stability testing.

Promising formulation candidates have successfully been evaluated and are continuously optimized within the development program since its launch in mid 2013.

Financial terms of the current agreement are not disclosed.


Advertisement